Adriamycin Pfs

Sezary Syndrome, Acute Lymphoblastic Leukemia, Urinary Bladder Neoplasms + 20 more

Treatment

2 FDA approvals

20 Active Studies for Adriamycin Pfs

What is Adriamycin Pfs

Doxorubicin

The Generic name of this drug

Treatment Summary

Doxorubicin is an antibiotic used to treat cancer. It comes from a type of bacteria called Streptomyces peucetius var. caesius. The drug works by binding to the DNA of cancer cells and preventing them from growing and spreading.

Doxorubicin Hydrochloride

is the brand name

image of different drug pills on a surface

Adriamycin Pfs Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Doxorubicin Hydrochloride

Doxorubicin

1987

117

Approved as Treatment by the FDA

Doxorubicin, otherwise known as Doxorubicin Hydrochloride, is approved by the FDA for 2 uses which include Multiple Myeloma and Multiple Myeloma (MM) .

Multiple Myeloma

Used to treat Multiple Myeloma (MM) in combination with Bortezomib

Multiple Myeloma (MM)

Used to treat Multiple Myeloma (MM) in combination with Bortezomib

Effectiveness

How Adriamycin Pfs Affects Patients

Doxorubicin is a medication used to treat different types of cancer. It works by interfering with the DNA of cancer cells and stopping them from growing. It is often used to treat solid tumors, while other forms of the drug are used to treat leukemia. Doxorubicin can also stop the activity of certain enzymes, affect gene expression, and cause damage to DNA. This drug is not specific to any stage of the cell cycle, so it affects all cancer cells.

How Adriamycin Pfs works in the body

Doxorubicin works by blocking the activity of an enzyme called topoisomerase II. It also forms a complex with DNA, preventing cells from reproducing. These two mechanisms work together to stop the spread of cancer cells.

When to interrupt dosage

The prescribed measure of Adriamycin Pfs is dependent upon the diagnosed condition, such as Malignant Lymphomas, Neoplasms and Sezary Syndrome. The dosage is contingent upon the mode of administration (e.g. Injectable, liposomal or Injection, solution) featured in the table below.

Condition

Dosage

Administration

Acute Lymphoblastic Leukemia

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Hodgkin's Lymphoma

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Sarcoma

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Endometrial Neoplasms

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Neoplasm Metastasis

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Waldenstrom Macroglobulinemia

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Sezary Syndrome

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

advanced uterine sarcoma

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

advanced Thymoma

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Neoplasms

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Stomach Neoplasms

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Carcinoma, Bronchogenic

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Metastatic Breast Cancer

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Thyroid Neoplasms

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

leukemia

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Acquired Immunodeficiency Syndrome

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Multiple Myeloma

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Soft Tissue Sarcoma

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Lymphoma, Non-Hodgkin

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Mycosis Fungoides

, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical

Warnings

Adriamycin Pfs has four contraindications and should not be taken while experiencing any of the ailments listed in the subsequent table.

Adriamycin Pfs Contraindications

Condition

Risk Level

Notes

Severe Hepatic Impairment

Do Not Combine

severe persistent drug-induced myelosuppression

Do Not Combine

Heart Failure

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Adriamycin Pfs.

Common Adriamycin Pfs Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Doxorubicin is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Doxorubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Doxorubicin.

Abetimus

Major

The risk or severity of adverse effects can be increased when Doxorubicin is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Doxorubicin is combined with Acteoside.

Adriamycin Pfs Toxicity & Overdose Risk

The toxic dose of this drug in rats has been found to be 21800 micrograms per kilogram when administered subcutaneously.

image of a doctor in a lab doing drug, clinical research

Adriamycin Pfs Novel Uses: Which Conditions Have a Clinical Trial Featuring Adriamycin Pfs?

287 active trials are currently being conducted to explore the efficacy of Adriamycin Pfs in the management of advanced Soft Tissue Sarcoma (STS), Mycosis Fungoides (MF) and advanced Uterine Sarcoma.

Condition

Clinical Trials

Trial Phases

Lymphoma, Non-Hodgkin

1 Actively Recruiting

Phase 1

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Sezary Syndrome

9 Actively Recruiting

Phase 2, Phase 1

Multiple Myeloma

6 Actively Recruiting

Phase 1, Phase 2

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Waldenstrom Macroglobulinemia

8 Actively Recruiting

Phase 2, Phase 1

advanced uterine sarcoma

0 Actively Recruiting

Acquired Immunodeficiency Syndrome

0 Actively Recruiting

Carcinoma, Bronchogenic

0 Actively Recruiting

Thyroid Neoplasms

0 Actively Recruiting

Mycosis Fungoides

0 Actively Recruiting

advanced Thymoma

0 Actively Recruiting

Endometrial Neoplasms

0 Actively Recruiting

Neoplasms

0 Actively Recruiting

Sarcoma, Bone

8 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1

Urinary Bladder Neoplasms

22 Actively Recruiting

Phase 1, Phase 2, Phase 3

Neuroblastoma

0 Actively Recruiting

Soft Tissue Sarcoma

51 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3

Hodgkin's Lymphoma

63 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1

Sarcoma

6 Actively Recruiting

Phase 1, Phase 2

Adriamycin Pfs Reviews: What are patients saying about Adriamycin Pfs?

4.3

Patient Review

11/18/2011

Adriamycin Pfs for Liver Cancer

I found this treatment to be effective and easy to use. All in all, I'm quite satisfied with my experience.

1.7

Patient Review

1/1/2014

Adriamycin Pfs for Breast Cancer that has Spread to Another Part of the Body

I really dislike this medication. After just two treatments, my neutrophil counts were low, and after the third treatment (with a two week break in between to recover), they were even lower. I also had low hemoglobin counts, which forced me to receive a blood transfusion. I feel nauseated and have more pain in my spine since being on this medication, and I don't know if it's helping or not.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about adriamycin pfs

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Adriamycin?

"nausea and vomiting, diarrhea, loss of appetite, missed menstrual periods, darkening of your skin or nails, weakness, tiredness, and eye redness."

Answered by AI

What is Adriamycin used to treat?

"Adriamycin is a medication used to treat various types of cancers, including breast cancer, bladder cancer, ovarian cancer, and thyroid cancer. It is also used to treat Hodgkin lymphoma, non-Hodgkin lymphoma, and certain types of leukemia."

Answered by AI

What does Adriamycin do to cancer?

"Adriamycin is a cancer medicine that belongs to a class of drugs called anthracyclines. It works by damaging the DNA inside cancer cells, which prevents them from replicating. Adriamycin works at any point in the cell cycle."

Answered by AI

What kind of chemo is Adriamycin?

"Some health care professionals may use the trade names Adriamycin or Rubex instead of the generic drug name Doxorubicin when referring to it. Doxorubicin is an anti-cancer chemotherapy drug, also known as an antineoplastic or cytotoxic drug."

Answered by AI

Clinical Trials for Adriamycin Pfs

Image of National Institutes of Health Clinical Center in Bethesda, United States.

CD22 CAR T-cells for Acute Lymphoblastic Leukemia

3 - 65
All Sexes
Bethesda, MD

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells. CAR T-cell therapy that targets a marker called CD19 has been show to can cure ALL in many children and adults. But in about 50% of patients, the ALL comes back within a year. Researchers want to find out if a second treatment with CAR T-cell therapy that targets a different marker, CD22, can keep the cancer away longer. Objective: To see if CD22 CAR T-cell therapy can keep ALL away longer. Eligibility: People aged 3 to 65 years who have no signs of cancer after CD19 CAR T-cell treatment for ALL. Design: Participants will be screened. They will have imaging scans and tests of their heart function. A sample of tissue (biopsy) will be collected from their bone marrow. They will have a fluid sample collected from the area around their spinal cord. Participants will undergo collection of their white blood cells (T cells) during a procedure called leukapheresis. Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The cells will be altered in a lab to create CD22 CAR T-cell therapy. Participants will take drugs over 4 consecutive days to prepare their body for the CAR T-cell therapy; then they will receive their modified T cells through a tube inserted into a vein. Some people may need to stay in the hospital during treatment. Participants will have follow-up visits for 2 years.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Sara K Silbert, M.D.

Image of University of Nebraska Medical Center in Omaha, United States.

Exercise for Blood Cancer Survivors

18+
All Sexes
Omaha, NE

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Phase 2
Waitlist Available

University of Nebraska Medical Center

Have you considered Adriamycin Pfs clinical trials?

We made a collection of clinical trials featuring Adriamycin Pfs, we think they might fit your search criteria.
Go to Trials
Image of The University of Arizona Cancer Center in Tucson, United States.

DLI-X for Leukemia

Any Age
All Sexes
Tucson, AZ

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. Additionally, the study aims to assess the safety and efficacy of therapeutic DLI-X (t-DLI-X) compared to t-DLI alone in patients with minimal residual disease (MRD+) or overt relapse post-alloHCT. For patients with CD19-positive lymphoid malignancies, the study will incorporate blinatumomab, while those with myeloid or CD19-negative lymphoid malignancies will receive t-DLI-X or t-DLI alone. We hypothesize that both pro-DLI-X and t-DLI-X, with or without blinatumomab, will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).

Phase 1
Waitlist Available

The University of Arizona Cancer Center

Emmanuel Katsanis, MD

Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN

This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.

Phase 2
Waitlist Available

St. Jude Children's Research Hospital

Stephanie B Dixon, MD, MPH

Have you considered Adriamycin Pfs clinical trials?

We made a collection of clinical trials featuring Adriamycin Pfs, we think they might fit your search criteria.
Go to Trials
Image of Carolina Biooncology in Huntersville, United States.

RNDO-564 + Pembrolizumab for Bladder Cancer

18+
All Sexes
Huntersville, NC

The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab. The study is focused on participants with certain solid tumors that are in an advanced stage and have certain tumor makers. This will be done by measuring the side effects that participants experience and how severe they are. Additionally, the study will evaluate how RNDO-564 moves into, through, and out of the body and how the treatment affects the body. The second goal of this study is to evaluate how well RNDO-564 works by itself or in combination with pembrolizumab at treating participants' cancer. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. Participants will take RNDO-564 weekly on Days 1, 8 and 15 of a 21 day cycle. Participants in the combination arms will take RNDO-564 as described with pembrolizumab every 3 weeks.

Phase 1
Recruiting

Carolina Biooncology (+1 Sites)

Thomas Manley, MD

Rondo Therapeutics

Have you considered Adriamycin Pfs clinical trials?

We made a collection of clinical trials featuring Adriamycin Pfs, we think they might fit your search criteria.
Go to Trials